Altimmune, Inc. short interest in 2020
In 2020, Altimmune, Inc.'s disclosed short interest ran from 1.76% of shares outstanding on 15 Jan 2020 to 8.85% on 31 Dec 2020, a change of +7.09 percentage points. The year's high was 19.11% on 29 May 2020 and its low 1.57% on 14 Feb 2020, averaging 8.17% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.98 days on 15 Jan 2020. Full history: Altimmune, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 1.76% (15 Jan 2020)
- End of year
- 8.85% (31 Dec 2020)
- Change
- +7.09 pp
- High
- 19.11% (29 May 2020)
- Low
- 1.57% (14 Feb 2020)
- Average
- 8.17%
- Highest days to cover
- 3.98 (15 Jan 2020)
- SEC filings marked
- 9
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 1.76% | 3.98 | |
| 31 Jan 2020 | 1.69% | 1.00 | |
| 14 Feb 2020 | 1.57% | 1.71 | |
| 28 Feb 2020 | 1.61% | 1.00 | |
| 31 Mar 2020 | 12.94% | 1.56 | 10-K filed, results (8-K) |
| 15 Apr 2020 | 11.68% | 1.90 | |
| 30 Apr 2020 | 10.62% | 3.27 | |
| 15 May 2020 | 12.09% | 1.00 | 10-Q filed, results (8-K) |
| 29 May 2020 | 19.11% | 1.00 | |
| 15 Jun 2020 | 17.19% | 1.41 | |
| 30 Jun 2020 | 12.56% | 1.00 | |
| 15 Jul 2020 | 14.18% | 1.00 | |
| 14 Aug 2020 | 2.71% | 1.00 | results (8-K), 10-Q filed, results (8-K) |
| 31 Aug 2020 | 3.11% | 1.00 | |
| 15 Sep 2020 | 4.46% | 1.14 | |
| 30 Sep 2020 | 6.33% | 1.28 | |
| 15 Oct 2020 | 7.06% | 1.02 | |
| 30 Oct 2020 | 8.85% | 3.43 | |
| 13 Nov 2020 | 7.30% | 1.43 | 10-Q filed, results (8-K) |
| 30 Nov 2020 | 6.60% | 1.60 | |
| 15 Dec 2020 | 7.52% | 1.09 | |
| 31 Dec 2020 | 8.85% | 1.81 |
See also: Altimmune, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.